To date, tirzepatide, also known as LY3298176, is the only promising dual GIP/GLP-1 receptor agonist ( in vitro ( Though the exact mechanisms underlying GLP-1/GIP synergism are unclear, some hypotheses have suggested that GIP operates directly via the CNS by reducing food intake, increasing the anorexigenic action of GLP-1, or enhancing tolerability to GLP-1R agonists ( Figure 2 )
Studies and clinical trials have shown that these medications can help sustain weight loss over the long term when used as part of a comprehensive treatment plan that includes diet and exercise
Take a look at this playwright's board, divided into four color-coded acts, each packed with cards holding text, images, and reference files
Blue Cross began covering Saxenda in 2015 when federal regulators approved it to treat weight loss, adding coverage of Wegovy in 2021 and Zepbound in 2023
Overall, I highly recommend